HCM
CLLS

Highbridge Capital Management’s Cellectis CLLS Stock Holding History

Highbridge Capital Management’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-13,905
Closed -$481K – 1421
2015
Q1 		$481K Buy
+13,905
New +$505K 0.01% 979

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

Highbridge Capital Management's CLLS Position: Q2 2015 in Review

Highbridge Capital Management sold out of Cellectis (CLLS) in Q2 2015, closing a stake of 13,905 shares — an estimated $481K sold.

Highbridge Capital Management first reported a position in CLLS in Q1 2015 and held it in 1 quarter. The position peaked at $481K in Q1 2015. 40 funds tracked by Wall St. Rank hold CLLS as of Q2 2015.

  • Highbridge Capital Management reported no remaining Cellectis position as of Q2 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 13,905 Cellectis shares in Q2 2015, an estimated $481K.
  • Highbridge Capital Management first reported a position in Cellectis in Q1 2015 and held it in 1 quarter.
  • Highbridge Capital Management's Cellectis position peaked at $481K in Q1 2015.
  • 40 funds tracked by Wall St. Rank held Cellectis as of Q2 2015.

Based on Highbridge Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.